Contineum Therapeutics (NASDAQ:CTNM) Research Coverage Started at Robert W. Baird

Robert W. Baird initiated coverage on shares of Contineum Therapeutics (NASDAQ:CTNM) in a research note issued to investors on Tuesday, MarketBeat.com reports. The firm issued an outperform rating and a $32.00 price target on the stock.

Separately, Royal Bank of Canada upped their target price on Contineum Therapeutics from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Wednesday, August 14th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $29.50.

Contineum Therapeutics Stock Up 2.6 %

NASDAQ CTNM opened at $16.69 on Tuesday. Contineum Therapeutics has a 12-month low of $13.27 and a 12-month high of $22.00. The company has a fifty day simple moving average of $17.93 and a two-hundred day simple moving average of $17.64.

Contineum Therapeutics (NASDAQ:CTNM) last issued its earnings results on Tuesday, August 13th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.02). On average, research analysts expect that Contineum Therapeutics will post -2.04 earnings per share for the current year.

Hedge Funds Weigh In On Contineum Therapeutics

Institutional investors have recently modified their holdings of the stock. Versant Venture Management LLC acquired a new stake in Contineum Therapeutics during the second quarter worth about $16,169,000. Johnson & Johnson acquired a new stake in shares of Contineum Therapeutics during the 2nd quarter worth approximately $34,853,000. Perceptive Advisors LLC purchased a new position in shares of Contineum Therapeutics during the 2nd quarter valued at approximately $27,589,000. Squarepoint Ops LLC acquired a new position in shares of Contineum Therapeutics in the 2nd quarter valued at $2,642,000. Finally, Rhumbline Advisers purchased a new stake in Contineum Therapeutics during the second quarter worth $118,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).